Experimental drug targets hardened skin in rare autoimmune disease
NCT ID NCT05214794
Summary
This study tested whether a drug called nemolizumab could help people with systemic sclerosis, a rare disease that causes skin thickening and can affect internal organs. Six patients with moderate to severe skin symptoms received the drug for up to a year. Researchers measured changes in skin thickness, lung function, and daily activity ability to see if the treatment was effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Tokyo Hospital
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.